Novartis drops PhII Parkinson's program

 
• By Eleanor Malone
  
Generate a summary of this article
Listen to this article
Beta

Novartis has discontinued development of the investigative compound AFQ056 to treat the jerky motions and tics that are a side-effect of treatment with levodopa in patients with Parkinson's disease. The firm had been planning to file its first regulatory approval submissions in this indication in 2015. However, the product failed to show efficacy in Parkinson's disease levodopa-induced dyskinesia (PD-LID) in recent Phase II studies.

Novartis has discontinued development of the investigative compound AFQ056 to treat the jerky motions and tics that are a side-effect of treatment with levodopa in patients with Parkinson's disease. The firm had been planning to file its first regulatory approval submissions in this indication in 2015. However, the product failed to show efficacy in Parkinson's disease levodopa-induced dyskinesia (PD-LID) in recent Phase II studies.

AFQ056, also known as mavoglurant, is an oral small molecule metabotropic glutamate 5 (mGluR5) antagonist. Novartis said that no safety...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Musculoskeletal

Lilly In No Hurry To Share Results From Muscle-Building And Obesity Combination

 
• By Andrew McConaghie

A new muscle-building front is opening in the fight against obesity, with Lilly among the leaders. But it plans to remain tight-lipped on upcoming Phase II data for its myostatin inhibitor in combination with Novo’s Wegovy for fear of playing into the hands of its rival.

Ultragenyx Data De-Risk Phase III Trial Of Setrusumab

 
• By Joseph Haas

The Mereo-partnered drug is in pivotal development for osteogenesis imperfecta. Ultragenyx also recently reported positive Phase III data for a rare disease gene therapy.

Bridgebio Ready To Challenge BioMarin In Achondroplasia

 
• By Andrew McConaghie

The company sees a $5bn opportunity to treat children with achondroplasia and the less severe growth disorder variant, hypochondroplasia.

Dyne Hopes DM1 And DMD Mid-Stage Data Can Lead To Accelerated Approval

 
• By Joseph Haas

Phase I/II data for its ADC candidates in myotonic dystrophy type 1 and Duchenne muscular dystrophy indicate potential for biomarker-based accelerated approval in both diseases, Dyne asserts.

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.